52 related articles for article (PubMed ID: 8763055)
1. Determination of debrisoquine oxidation phenotype in healthy volunteers during phase I trials.
Girard I; Ferry S; Nony P; Boissel JP
Therapie; 1996; 51(2):191-2. PubMed ID: 8763055
[No Abstract] [Full Text] [Related]
2. Data on placebo in healthy volunteers: impact of experimental conditions on safety, and on laboratory and physiological variables during phase I trials.
Rosenzweig P; Brohier S; Zipfel A
Therapie; 1996; 51(4):356-7. PubMed ID: 8953805
[No Abstract] [Full Text] [Related]
3. Is there a link between debrisoquine oxidation phenotype and lung cancer susceptibility?
Horsmans Y; Desager JP; Harvengt C
Biomed Pharmacother; 1991; 45(8):359-62. PubMed ID: 1773024
[TBL] [Abstract][Full Text] [Related]
4. Tiracizine disposition in healthy volunteers with reference to the debrisoquine oxidation phenotype.
Berndt A; Hoffmann C; Richter K; Oertel R; Vierkant A; Siegmund W
Br J Clin Pharmacol; 1995 Sep; 40(3):287-8. PubMed ID: 8527295
[No Abstract] [Full Text] [Related]
5. Correlation between the metabolic ratios of debrisoquine and metoprolol in Turkish subjects.
Basci NE; Bozkurt A; Isimer A; Kayaalp SO
Pharmacol Toxicol; 1994 Jul; 75(1):62-4. PubMed ID: 7971736
[No Abstract] [Full Text] [Related]
6. Debrisoquine oxidation phenotype and susceptibility to lung cancer.
Boobis AR; Davies DS
Br J Clin Pharmacol; 1990 Oct; 30(4):653-6. PubMed ID: 2291880
[No Abstract] [Full Text] [Related]
7. Polymorphism of debrisoquine oxidation in New Zealand Caucasians.
Wanwimolruk S; Denton JR; Ferry DG; Beasley M; Broughton JR
Eur J Clin Pharmacol; 1992; 42(3):349-50. PubMed ID: 1577057
[No Abstract] [Full Text] [Related]
8. Debrisoquine oxidation polymorphism in patients with rheumatoid arthritis.
Benitez J; Ladero JM; Andres MP; Jover JA; Morado C; Bañares A
Ann Rheum Dis; 1994 Mar; 53(3):211. PubMed ID: 8154943
[No Abstract] [Full Text] [Related]
9. Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects.
Spina E; Ancione M; Di Rosa AE; Meduri M; Caputi AP
Eur J Clin Pharmacol; 1992; 42(3):347-8. PubMed ID: 1349529
[No Abstract] [Full Text] [Related]
10. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
[TBL] [Abstract][Full Text] [Related]
11. Oxidation phenotype and beta-blockers.
N Engl J Med; 1983 Apr; 308(16):964-6. PubMed ID: 6132337
[No Abstract] [Full Text] [Related]
12. Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine.
Sachse C; Brockmöller J; Hildebrand M; Müller K; Roots I
Pharmacogenetics; 1998 Apr; 8(2):181-5. PubMed ID: 10022755
[No Abstract] [Full Text] [Related]
13. Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine.
Bernal ML; Sinues B; Johansson I; McLellan RA; Wennerholm A; Dahl ML; Ingelman-Sundberg M; Bertilsson L
Pharmacogenetics; 1999 Oct; 9(5):657-60. PubMed ID: 10591547
[No Abstract] [Full Text] [Related]
14. Determination of oxidation phenotype by measurement of propafenone urinary metabolic ratios.
Lledó P; Johnston A; Walker S; Pearson RM; Turner P
Hum Exp Toxicol; 1993 Mar; 12(2):161-3. PubMed ID: 8096716
[No Abstract] [Full Text] [Related]
15. Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.
LLerena A; de la Rubia A; Berecz R; Dorado P
Pharmacopsychiatry; 2004 Mar; 37(2):69-73. PubMed ID: 15048614
[TBL] [Abstract][Full Text] [Related]
16. [CYP 2D6 activity profile among patients with depression].
Bidziński A; Koszewska I; Turzyńska D; Kalinowski A; Swiecicki L; Dabrowski M; Torbiński J; Burna-Drazkowic E; Fornal S; Gradzka D; Namysłowska M; Puzyński S; Płaźnik A
Psychiatr Pol; 2004; 38(6):1085-92. PubMed ID: 15779672
[TBL] [Abstract][Full Text] [Related]
17. Xenobiotic metabolism in motor neuron disease.
Steventon G; Williams AC; Waring RH; Pall HS; Adams D
Lancet; 1988 Sep; 2(8612):644-7. PubMed ID: 2901517
[TBL] [Abstract][Full Text] [Related]
18. Predicting debrisoquine phenotype.
Heim M; Meyer UA
Lancet; 1991 Feb; 337(8737):363. PubMed ID: 1671255
[No Abstract] [Full Text] [Related]
19. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis.
Christensen PM; Gøtzsche PC; Brøsen K
Pharmacogenetics; 1998 Dec; 8(6):473-9. PubMed ID: 9918130
[TBL] [Abstract][Full Text] [Related]
20. [Phenotypes of oxidation and acetylation in Alzheimer's disease--preliminary report].
Milejski P; Orzechowska-Juzwenko K; Niewiński P; Hurkacz M; Czarnik-Matusewicz H; Leszek J; Rudzik J; Grotthus B
Psychiatr Pol; 2007; 41(2):261-9. PubMed ID: 17598435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
